$DVAX News
Last published 10mo ago
- 10mo agoDVAXSanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the PipelinePR NewswireSanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines...
- 11mo agoDVAXDynavax to Participate at the 8th Annual Evercore Healthcare ConferencePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase ProgramPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine ProgramPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and ...
- 1y agoDVAXDynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025PR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of TrialPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax to Participate in the 2025 Wells Fargo Healthcare ConferencePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine ProfilePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDVAXDynavax Reports Second Quarter 2025 Financial ResultsPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025PR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual MeetingPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the BoardroomBusiness WireDeep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board
- 1y agoDVAXDynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual MeetingPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDynavax Comments on Glass Lewis RecommendationPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXGlass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax TechnologiesBusiness WireGlass Lewis Recommends Shareholders Vote FOR Deep Track Nominees Brett Erkman and Donald Santel and AGAINST Chairman Scott Myers and Director Brent MacGregor Notes that "Deep Track has Highlighted Valid and Critical
- 1y agoDVAXDynavax to Present at William Blair's 45th Annual Growth Stock ConferencePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDeep Track Capital Comments on ISS RecommendationBusiness WireStrongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market
- 1y agoDVAXLeading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director NomineesPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDeep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual MeetingBusiness WireCites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To-Date Share Price Decline, Underperformance Versus Benchmarks, Precipitous 11% Drop Post-First Quarter Earnings and Fresh
- 1y agoDVAXDynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term ValuePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued MomentumPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline ProgramsPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDeep Track Capital Releases Investor Presentation on Dynavax TechnologiesBusiness WireHighlights Opportunity to Unlock Value With Enhanced Boardroom Objectivity Details How Deep Track's Independent Nominees Will Prioritize Shareholder-Aligned Capital Allocation Decisions and Help Set Value-Maximizing
- 1y agoDVAXDynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection BenefitsPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation StrategyPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025PR NewswireDynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXMRNASNYTARS+4Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow ShareholdersBusiness WireBelieves Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on
- 1y agoDVAXDynavax Files Definitive Proxy Statement and Sends Letter to StockholdersPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXDeep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement OfferBusiness WireBelieves Company's Unwillingness to Reach Mutually Acceptable Resolution – And Opposition to Giving Shareholders a Voice in the Boardroom – Underscores the Board's Entrenchment and the Clear Need for Investor-Driven
- 1y agoDVAXDynavax Files Preliminary Proxy StatementPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoDVAXRXRXRecursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine SunGlobeNewswireSalt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and
- 1y agoBBIODVAXDeep Track Capital Sends Letter to Dynavax Technologies' Board of DirectorsBusiness WireNotes Investor Feedback Supporting Deep Track's Course of Action and Sharing Concerns with Company's Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom Highlights
- 1y agoDVAXDynavax Announces Convertible Debt Refinancing and Common Stock Share RepurchasePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has ...
- 1y agoDVAXDynavax to Participate in Upcoming Investor ConferencesPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial GuidancePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Responds to Deep Track and Highlights Long-Term Value Creation StrategyPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and...
- 1y agoAVTEDVAXHZNPMRNA+7Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingBusiness WireIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom
- 1y agoDVAXDynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025PR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax Advances Board Refreshment ProgramPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing...
- 1y agoDVAXDynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial HighlightsPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 1y agoDVAXDynavax to Present at the 7th Annual Evercore HealthCONx ConferencePR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXDynavax Announces $100 Million Accelerated Share Repurchase ProgramPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXDynavax Technologies Corporation (DVAX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDVAXDynavax Reports Third Quarter 2024 Financial Results and Provides Business UpdatesPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXDynavax Announces $200 Million Share Repurchase ProgramPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXDynavax Adopts Limited-Duration Stockholder Rights PlanPR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXDynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024PR NewswireDynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...
- 2y agoDVAXLNTHLantheus Appoints Julie Eastland as New Board MemberGlobeNewswireBEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 2y agoDVAXDynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts